Health & Nutrition
Neuralink rival Synchron's brain implant now lets people...
Neuralink competitor Synchron announces integration with Apple Vision Pro.
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's...
Liraglutide is sold under the brand names Saxenda and Victoza, and sales are declining...
We're encouraged by Abbott stock trading but discouraged...
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon...
Merck beats earnings expectations, raises sales outlook...
The drugmaker raised its full-year sales forecast to $63.4 billion to $64.4 billion...
Pfizer beats earnings estimates, hikes full-year outlook...
The results come as Pfizer scrambles to stabilize its business and win back Wall...
Obesity and a Toxic Food Environment
Implausible explanations for the obesity epidemic serve the needs of food manufacturers...
We're making a flurry of moves: trimming 2 stocks and buying...
The trades come ahead of a busy week of earnings for the Investing Club portfolio.
An ugly earnings report from a competitor is good news...
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
Dexcom shares plunge more than 40% for worst day on record
Dexcom, which had its stock market debut in 2005, had its worst day ever after lowering...
Viking Therapeutics stock jumps nearly 30% after drugmaker...
It brings the drugmaker one step closer to joining the market for GLP-1s, which...
